Oct 23 | Neuromuscular Drug Development Summit (NMD) | Boston, MA Patch
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
News — NMD Pharma
NMD Pharma - Inkef capital
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
Annual Report 2018 by Lundbeckfonden - issuu
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
Biopeople Newsletter January 2020 - Biopeople
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
NMD Pharma - Inkef capital
NMD Pharma - PIR International
NMD Pharma treats first patient with the firm's most promising drug candidate
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
Biotech completes financing round to advance neuromuscular treatments - EPM Magazine
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
NMD Pharma A/S | LinkedIn
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Dutch MG Clinical Trial Will Test NMD670 Oral Therapy Candidate
Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents
Management — NMD Pharma
NMD Pharma - Inkef capital
NMD Pharma - PIR International
Management — NMD Pharma
Prominent Canadian researcher in Denmark: Why I left a top job in California
